Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis – current evidence and potential clinical applications

  • Y. Touchefeu
    Institut des Maladies de l'Appareil Digestif Centre Hospitalier Universitaire de Nantes Nantes France
  • E. Montassier
    Faculté de Médecine Laboratoire EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections Université de Nantes Nantes France
  • K. Nieman
    Biofortis Clinical Research Addison IL USA
  • T. Gastinne
    Service d'Hématologie Clinique Centre Hospitalier Universitaire de Nantes Nantes France
  • G. Potel
    Faculté de Médecine Laboratoire EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections Université de Nantes Nantes France
  • S. Bruley des Varannes
    Institut des Maladies de l'Appareil Digestif Centre Hospitalier Universitaire de Nantes Nantes France
  • F. Le Vacon
    Biofortis SAS Saint‐Herblain France
  • M. F. de La Cochetière
    Faculté de Médecine Laboratoire EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections INSERM Université de Nantes Nantes France

説明

<jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Gastrointestinal mucositis is defined as inflammation and/or ulcers of the gastrointestinal tract occurring as a complication of chemotherapy and radiation therapy, and affects about 50% of all cancer patients.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To assess the role of gut microbiota in the pathogenesis of gastrointestinal mucositis and the potential for manipulations of the microbiota to prevent and to treat mucositis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Search of the literature published in English using Medline, Scopus and the Cochrane Library, with main search terms ‘intestinal microbiota’, ‘bacteremia’, ‘mucositis’, ‘chemotherapy‐induced diarrhoea’, ‘chemotherapy‐induced mucositis’, ‘radiotherapy‐induced mucositis’.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The gut microbiota plays a major role in the maintenance of intestinal homoeostasis and integrity. Patients receiving cytotoxic and radiation therapy exhibit marked changes in intestinal microbiota, with most frequently, decrease in <jats:italic>Bifidobacterium</jats:italic>,<jats:italic> Clostridium</jats:italic> cluster <jats:styled-content style="fixed-case">XIV</jats:styled-content>a, <jats:italic>Faecalibacterium prausnitzii</jats:italic>, and increase in <jats:italic>Enterobacteriaceae</jats:italic> and <jats:italic>Bacteroides</jats:italic>. These modifications may contribute to the development of mucositis, particularly diarrhoea and bacteraemia. The prevention of cancer therapy‐induced mucositis by probiotics has been investigated in randomised clinical trials with some promising results. Three of six trials reported a significantly decreased incidence of diarrhoea. One trial reported a decrease in infectious complications.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The gut microbiota may play a major role in the pathogenesis of mucositis through the modification of intestinal barrier function, innate immunity and intestinal repair mechanisms. Better knowledge of these effects may lead to new therapeutic approaches and to the identification of predictive markers of mucositis.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ